Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2022

Upgrades

• Guggenheim upgraded the previous rating for Salesforce Inc CRM from Sell to Neutral. For the second quarter, Salesforce had an EPS of $1.19, compared to year-ago quarter EPS of $1.48. The stock has a 52-week-high of $256.87 and a 52-week-low of $150.87. At the end of the last trading period, Salesforce closed at $153.53.
• For Okta Inc OKTA, Guggenheim upgraded the previous rating of Sell to Neutral. In the second quarter, Okta showed an EPS of $0.10, compared to $0.11 from the year-ago quarter. At the moment, the stock has a 52-week-high of $226.49 and a 52-week-low of $58.12. Okta closed at $60.60 at the end of the last trading period.
• For Advent Technologies Holdings Inc ADN, Credit Suisse upgraded the previous rating of Underperform to Neutral. In the second quarter, Advent Technologies Hldgs showed an EPS of $0.21, compared to $0.07 from the year-ago quarter. The current stock performance of Advent Technologies Hldgs shows a 52-week-high of $7.08 and a 52-week-low of $1.13. Moreover, at the end of the last trading period, the closing price was at $3.10.

See all analyst ratings upgrades.

Downgrades

• Needham downgraded the previous rating for C3.ai Inc AI from Buy to Hold. In the first quarter, C3.ai showed an EPS of $0.12, compared to $0.22 from the year-ago quarter. The stock has a 52-week-high of $32.36 and a 52-week-low of $13.37. At the end of the last trading period, C3.ai closed at $14.52.
• Seaport Global downgraded the previous rating for Tilly's Inc TLYS from Buy to Neutral. In the second quarter, Tilly's showed an EPS of $0.13, compared to $0.66 from the year-ago quarter. The current stock performance of Tilly's shows a 52-week-high of $16.95 and a 52-week-low of $6.87. Moreover, at the end of the last trading period, the closing price was at $7.33.
• According to Credit Suisse, the prior rating for Forma Therapeutics Holdings Inc FMTX was changed from Outperform to Neutral. Forma Therapeutics Hldgs earned $1.10 in the second quarter, compared to $0.92 in the year-ago quarter. The current stock performance of Forma Therapeutics Hldgs shows a 52-week-high of $20.28 and a 52-week-low of $4.95. Moreover, at the end of the last trading period, the closing price was at $20.24.
• According to RBC Capital, the prior rating for Azure Power Global Ltd AZRE was changed from Outperform to Sector Perform. For the third quarter, Azure Power Global had an EPS of $0.13, compared to year-ago quarter EPS of $0.31. The current stock performance of Azure Power Global shows a 52-week-high of $21.53 and a 52-week-low of $3.26. Moreover, at the end of the last trading period, the closing price was at $3.68.
• HC Wainwright & Co. downgraded the previous rating for Forma Therapeutics Holdings Inc FMTX from Buy to Neutral. Forma Therapeutics Hldgs earned $1.10 in the second quarter, compared to $0.92 in the year-ago quarter. The stock has a 52-week-high of $20.28 and a 52-week-low of $4.95. At the end of the last trading period, Forma Therapeutics Hldgs closed at $20.24.
• According to JP Morgan, the prior rating for LyondellBasell Industries NV LYB was changed from Overweight to Neutral. LyondellBasell Industries earned $5.19 in the second quarter, compared to $6.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $117.22 and a 52-week-low of $80.74. LyondellBasell Industries closed at $81.86 at the end of the last trading period.
• For Dow Inc DOW, JP Morgan downgraded the previous rating of Overweight to Neutral. For the second quarter, Dow had an EPS of $2.31, compared to year-ago quarter EPS of $2.72. At the moment, the stock has a 52-week-high of $71.86 and a 52-week-low of $48.27. Dow closed at $49.96 at the end of the last trading period.

See all analyst ratings downgrades.

Initiations

• With a Neutral rating, Atlantic Equities initiated coverage on Palo Alto Networks Inc PANW. The price target seems to have been set at $495.00 for Palo Alto Networks. In the fourth quarter, Palo Alto Networks showed an EPS of $2.39, compared to $1.60 from the year-ago quarter. The stock has a 52-week-high of $640.90 and a 52-week-low of $421.55. At the end of the last trading period, Palo Alto Networks closed at $545.15.
• For ProKidney Corp PROK, Evercore ISI Group initiated coverage, by setting the current rating at Outperform. In the second quarter, ProKidney showed an EPS of $0.12, compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $11.98 and a 52-week-low of $6.19. At the end of the last trading period, ProKidney closed at $9.67.
• Stifel initiated coverage on Greif Inc GEF with a Buy rating. The price target for Greif is set to $90.00. In the third quarter, Greif showed an EPS of $2.35, compared to $1.93 from the year-ago quarter. At the moment, the stock has a 52-week-high of $72.80 and a 52-week-low of $53.65. Greif closed at $65.50 at the end of the last trading period.
• With an Overweight rating, Wells Fargo initiated coverage on PROCEPT BioRobotics Corp PRCT. The price target seems to have been set at $49.00 for PROCEPT BioRobotics. At the moment, the stock has a 52-week-high of $46.62 and a 52-week-low of $15.38. PROCEPT BioRobotics closed at $40.38 at the end of the last trading period.
• With a Neutral rating, Atlantic Equities initiated coverage on CrowdStrike Holdings Inc CRWD. The price target seems to have been set at $200.00 for CrowdStrike Holdings. In the second quarter, CrowdStrike Holdings showed an EPS of $0.36, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $242.00 and a 52-week-low of $130.00. At the end of the last trading period, CrowdStrike Holdings closed at $172.97.
• Atlantic Equities initiated coverage on Fortinet Inc FTNT with an Overweight rating. The price target for Fortinet is set to $76.00. In the second quarter, Fortinet showed an EPS of $0.24, compared to $0.19 from the year-ago quarter. The stock has a 52-week-high of $362.12 and a 52-week-low of $47.37. At the end of the last trading period, Fortinet closed at $48.55.
• With a Buy rating, Stifel initiated coverage on Relay Therapeutics Inc RLAY. The price target seems to have been set at $40.00 for Relay Therapeutics. For the second quarter, Relay Therapeutics had an EPS of $0.71, compared to year-ago quarter EPS of $0.64. The current stock performance of Relay Therapeutics shows a 52-week-high of $35.36 and a 52-week-low of $12.65. Moreover, at the end of the last trading period, the closing price was at $24.90.

See all analyst ratings initiations.